Recombinant IL-15 had been reported to evoke anti-tumor activity of adaptive and innate immune cells in colon cancer (70) however, Short half-life and poor bioavailability limit the therapeutic potential of IL-15 systemic therapy. Here, IL15 is linked to malignant colon neoplasm.